SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

Core Insights - Preclinical data supports SLS009 as a promising treatment for T-cell prolymphocytic leukemia (T-PLL), both as a monotherapy and in combination with venetoclax [1][2][3] Group 1: Efficacy of SLS009 - SLS009 demonstrated significant single-agent activity and improved overall survival in a patient-derived xenograft model of relapsed/refractory T-PLL, with survival times of 7.4 weeks for SLS009 monotherapy and 7.9 weeks for the combination with venetoclax, compared to 4.4 weeks for venetoclax alone [2][3] - The combination of SLS009 and venetoclax was well tolerated, indicating a favorable safety profile [2][3] Group 2: Research Presentation - The findings will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled for October 17-21, 2025, in Berlin, Germany [1][4] - The poster presentation is titled "CDK9 Inhibition Enhances Venetoclax Activity and Prolongs Survival in a T-PLL Patient-Derived Xenograft Model" [4] Group 3: Company Overview - SELLAS Life Sciences Group, Inc. is focused on developing novel therapies for various cancer indications, with SLS009 being a key candidate as a differentiated small molecule CDK9 inhibitor [5][6] - The company also has a lead product candidate, GPS, which targets the WT1 protein and has potential applications in multiple hematologic malignancies and solid tumors [5]